Francisca FERRER MARÍN

Alvarez-Larran A, Garrote M, Ferrer-Marin F, Perez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gomez M, Garcia R, Garcia-Gutierrez V, Gasior M, Cuevas B, Angona A, Gomez-Casares MT, Martinez CM, Magro E, Ayala R, Del Orbe-Barreto R, Perez-Lopez R, Fox ML, Raya JM, Guerrero L, Garcia-Hernandez C, Caballero G, Murillo I, Xicoy B, Ramirez MJ, Carreno-Tarragona G, Hernandez-Boluda JC, Pereira A; MPN Spanish Group (Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas). Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. PubMed PMID: 35417564; PubMed Central PMCID: PMC9324831.

AÑO: 2022; IF: 6.2

35417564

Garcia-Fortes M, Hernandez-Boluda JC, Alvarez-Larran A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, Garcia-Hernandez MC, Gomez-Casares MT, Ferrer-Marin F, Saavedra S, Cervantes F, Garcia-Delgado R, On Behalf Of The Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers (Basel). 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. PubMed PMID: 35565461; PubMed Central PMCID: PMC9104306.

AÑO: 2022; IF: 6.575

35565461

Estrada N, Zamora L, Ferrer-Marin F, Palomo L, Garcia O, Velez P, De la Fuente I, Sagues M, Cabezon M, Cortes M, Vallansot RO, Senin-Magan MA, Boque C, Xicoy B. Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients. J Clin Med. 2022 Oct 21;11(20):6217. doi: 10.3390/jcm11206217. PubMed PMID: 36294538; PubMed Central PMCID: PMC9604607.

AÑO: 2022; IF: 4.964

36294538

Orti G, Garcia-Gutierrez V, Bautista G, Ferrer-Marin F, Vallansot R, Xicoy B, Sanchez A, Simon I, Triguero A, Sierra M, Casado LF; Grupo Espanol de Leucemia Mieloide Cronica (GELMC). Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia. Leuk Res. 2022 Oct;121:106923. doi: 10.1016/j.leukres.2022.106923. Epub 2022 Aug 4. No abstract available. PubMed PMID: 35933910.

AÑO: 2022; IF: 2.7

35933910

Sanchez R, Dorado S, Ruiz-Heredia Y, Martin-Munoz A, Rosa-Rosa JM, Ribera J, Garcia O, Jimenez-Ubieto A, Carreno-Tarragona G, Linares M, Rufian L, Juarez A, Carrillo J, Espino MJ, Caceres M, Exposito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernandez-Rivas JA, Bravo P, Seri C, Anguita E, Barragan E, Sargas C, Ferrer-Marin F, Sanchez-Calero J, Sevilla J, Ruiz E, Villalon L, Del Mar Herraez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, Garcia-Gutierrez V, Ayala R, Ribera JM, Barrio S, Martinez-Lopez J. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Sci Rep. 2022 Jul 29;12(1):13057. doi: 10.1038/s41598-022-17271-3. Erratum In: Sci Rep. 2024 Mar 28;14(1):7400. PubMed PMID: 35906470; PubMed Central PMCID: PMC9338264.

AÑO: 2022; IF: 4.6

35906470